A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
- Ages16 - 75 years
- Trial withJanssen Pharmaceuticals
- Start Date06/30/2019
- End Date01/21/2021
- Last Updated07/02/2019
- Study HIC#2000022990